510 related articles for article (PubMed ID: 37414756)
1. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management.
Shyam Sunder S; Sharma UC; Pokharel S
Signal Transduct Target Ther; 2023 Jul; 8(1):262. PubMed ID: 37414756
[TBL] [Abstract][Full Text] [Related]
2. Expert consensus of management of adverse drug reactions with anaplastic lymphoma kinase tyrosine kinase inhibitors.
Zhou F; Yang Y; Zhang L; Cheng Y; Han B; Lu Y; Wang C; Wang Z; Yang N; Fan Y; Wang L; Ma Z; Zhang L; Yao Y; Zhao J; Dong X; Zhu B; Zhou C
ESMO Open; 2023 Jun; 8(3):101560. PubMed ID: 37230029
[TBL] [Abstract][Full Text] [Related]
3. Clinical Management of Adverse Events Associated with Lorlatinib.
Bauer TM; Felip E; Solomon BJ; Thurm H; Peltz G; Chioda MD; Shaw AT
Oncologist; 2019 Aug; 24(8):1103-1110. PubMed ID: 30890623
[TBL] [Abstract][Full Text] [Related]
4. Practical recommendation for rash and diarrhea management in Indian patients treated with tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
Parikh P; Prabhash K; Naik R; Vaid AK; Goswami C; Rajappa S; Noronha V; Joshi A; Chacko RT; Aggarwal S; Doval DC
Indian J Cancer; 2016; 53(1):87-91. PubMed ID: 27146751
[TBL] [Abstract][Full Text] [Related]
5. Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors.
Lenihan DJ; Kowey PR
Oncologist; 2013; 18(8):900-8. PubMed ID: 23918069
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics and outcomes of tyrosine kinase inhibitor-related lower GI adverse effects.
Liu C; Amin R; Shatila M; Short N; Altan M; Shah A; Alhalabi O; Okhuysen P; Thomas AS; Wang Y
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3965-3976. PubMed ID: 36030431
[TBL] [Abstract][Full Text] [Related]
7. Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors.
Li J; Wang M; Zhang B; Wu X; Lin TL; Liu XF; Zhou Y; Zhang XH; Xu H; Shen LJ; Zou J; Lu P; Zhang D; Gu WJ; Zhang MX; Pan J; Cao H;
World J Gastroenterol; 2018 Dec; 24(46):5189-5202. PubMed ID: 30581268
[TBL] [Abstract][Full Text] [Related]
8. Tyrosine kinase inhibitor-induced hypothyroidism: mechanism and clinical implications.
Wang Z; Wang H; Bu C; Meng B; Mu Y; Gao S; Chen W; Tao X
Eur J Clin Pharmacol; 2024 Jun; 80(6):827-838. PubMed ID: 38483545
[TBL] [Abstract][Full Text] [Related]
9. Incidence of pneumonitis following the use of different anaplastic lymphoma kinase tyrosine kinase inhibitor regimens: An updated systematic review and meta-analysis.
Qie W; Zhao Q; Yang L; Zou B; Duan Y; Yao Y; Wang L
Cancer Med; 2023 Jul; 12(13):13873-13884. PubMed ID: 37017467
[TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and risk factors of drug-induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis.
Koshikawa K; Terada J; Abe M; Iwasawa S; Sakayori M; Yoshioka K; Hirasawa Y; Kasai H; Kawasaki Y; Tsushima K; Tatsumi K
Thorac Cancer; 2020 Jun; 11(6):1495-1502. PubMed ID: 32237210
[TBL] [Abstract][Full Text] [Related]
11. The effects of switching EGFR-TKI treatments for non-small cell lung cancer because of adverse events.
Sakata Y; Kawamura K; Shingu N; Hiroshige S; Yasuda Y; Eguchi Y; Anan K; Hisanaga J; Nitawaki T; Nakano A; Ichikado K
Asia Pac J Clin Oncol; 2020 Apr; 16(2):e113-e117. PubMed ID: 30506897
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring.
Josephs DH; Fisher DS; Spicer J; Flanagan RJ
Ther Drug Monit; 2013 Oct; 35(5):562-87. PubMed ID: 24052062
[TBL] [Abstract][Full Text] [Related]
13. Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients.
Resteghini C; Cavalieri S; Galbiati D; Granata R; Alfieri S; Bergamini C; Bossi P; Licitra L; Locati LD
Best Pract Res Clin Endocrinol Metab; 2017 Jun; 31(3):349-361. PubMed ID: 28911730
[TBL] [Abstract][Full Text] [Related]
14. Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies.
Johnson M; Garassino MC; Mok T; Mitsudomi T
Lung Cancer; 2022 Aug; 170():41-51. PubMed ID: 35714425
[TBL] [Abstract][Full Text] [Related]
15. Advances in targeted therapy in non-small cell lung cancer with actionable mutations and leptomeningeal metastasis.
Li D; Song Z; Dong B; Song W; Cheng C; Zhang Y; Zhang W
J Clin Pharm Ther; 2022 Jan; 47(1):24-32. PubMed ID: 34309914
[TBL] [Abstract][Full Text] [Related]
16. Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring.
Schiefer M; Hendriks LEL; Dinh T; Lalji U; Dingemans AC
Eur J Cancer; 2018 Mar; 91():92-98. PubMed ID: 29413968
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular Toxicities of Small Molecule Tyrosine Kinase Inhibitors: An Opportunity for Systems-Based Approaches.
Brown SA; Nhola L; Herrmann J
Clin Pharmacol Ther; 2017 Jan; 101(1):65-80. PubMed ID: 27806435
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
19. [Chinese Expert Consensus on Management of Special Adverse Effects
Associated with Lorlatinib].
Zhou Q; Lu S; Li Y; Jia F; Li G; Hong Z; Lu Y; Fan Y; Zhou J; Liu Z; Li J; Wu YL; ;
Zhongguo Fei Ai Za Zhi; 2022 Aug; 25(8):555-566. PubMed ID: 36002192
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy.
Shah DR; Shah RR; Morganroth J
Drug Saf; 2013 Jun; 36(6):413-26. PubMed ID: 23620170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
